BioInvest In The News

Top Picks 2017: Madrigal (1-20-2017)
Top Picks 2017: The Medicines Company (1-18-2017)
Top Picks 2017: Incyte (1-06-2017)
10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)
Incyte: A Promising Pipeline (11-14-2016)
Company Updates
'Access to Management' Conference Call with Madrigal (MDGL)- 4-4-17

‘Access to Management’ Conference Call with Madrigal (MDGL)- 4-4-17

BIOINVEST Access to Management Webinar – Madrigal (MDGL)– We are pleased to announce another BioInvest “Access to Management Call.” Below is the link to the recorded webinar presentation with the Senior Management Team of Madrigal.

Esperion (ESPR)  02-20-17

Esperion (ESPR) 02-20-17

BIOINVEST BREAKING NEWS – Esperion Therapeutics (ESPR) – FDA Shows Esperion “The Way to Approval” – Raising BUY to 40 and TARGET PRICE to 60

This morning, ESPR announced that the FDA has confirmed that the bempedoic acid Phase III development program is adequate to support an approval prior to their CVOT results, lifting one of the largest overhangs on the stock, and creating a clear path to an earlier-than-expected approval.

Nektar (NKTR) 02-20-17

Nektar (NKTR) 02-20-17

BIOINVEST BREAKING NEWS – Nektar (NKTR) – NKTR-181 Successful In Phase III SUMMIT-07 Trial & Sets The Stage For A Revolution In Pain Drugs – Raising BUY and TARGET PRICE

The SUMMIT-07 trial met its primary endpoint demonstrating highly significant improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019). Moreover, the safety and tolerability of ‘181 in SUMMIT supports its breakthrough profile for moderate-to-severe pain relief without the abuse and addiction that has caused the opioid epidemic of today